Crenolanib is a benzimidazole derivative with a 1H-benzimidazole core substituted at position 1 by an 8-(4-aminopiperidin-1-yl)quinolin-2-yl group and at position 5 by a (3-methyloxetan-3-yl)methoxy group. It inhibits type III tyrosine kinases, including PDGFRalpha/beta and FLT3, with IC50 values of 11, 3.2, and 4 nM, respectively. Under clinical development for acute myeloid leukemia, it functions as a receptor protein-tyrosine kinase inhibitor, angiogenesis inhibitor, antineoplastic agent, and apoptosis inducer. It belongs to benzimidazoles, aromatic ethers, quinolines, oxetanes, aminopiperidines, and tertiary amino compounds.
